We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Designates Preliminary Review Panel for Advanced Therapies
EMEA Designates Preliminary Review Panel for Advanced Therapies
February 17, 2009
The European Medicines Agency (EMEA) is turning to a new panel of experts to review gene- or cell-based treatments before the Committee for Medicinal Products for Human Use (CHMP) decides whether to recommend approval.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor